$0.82
2.01% yesterday
Nasdaq, May 20, 10:07 pm CET
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Coherus BioSciences, Inc. Stock price

$0.82
-0.24 23.01% 1M
-0.28 25.81% 6M
-0.56 40.86% YTD
-1.26 60.76% 1Y
-7.49 90.18% 3Y
-16.42 95.27% 5Y
-24.37 96.76% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.02 2.01%
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Key metrics

Market capitalization $94.61m
Enterprise Value $311.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 623.40
EV/Sales (TTM) EV/Sales 1.58
P/S ratio (TTM) P/S ratio 0.48
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -34.58%
Revenue (TTM) Revenue $197.50m
EBIT (operating result TTM) EBIT $-107.91m
Free Cash Flow (TTM) Free Cash Flow $500.00k
Cash position $82.41m
EPS (TTM) EPS $-1.13
P/E forward negative
P/S forward 1.65
EV/Sales forward 5.44
Short interest 29.22%
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Coherus BioSciences, Inc. forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
198 198
35% 35%
100%
- Direct Costs 90 90
50% 50%
46%
107 107
11% 11%
54%
- Selling and Administrative Expenses 126 126
33% 33%
64%
- Research and Development Expense 84 84
14% 14%
43%
-103 -103
38% 38%
-52%
- Depreciation and Amortization 4.82 4.82
5% 5%
2%
EBIT (Operating Income) EBIT -108 -108
37% 37%
-55%
Net Profit -131 -131
121% 121%
-66%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Neutral
Seeking Alpha
8 days ago
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer Theresa LaVallee - Chief Scientific & Development Officer Rosh Dias - Chief Medical Officer Sameer Goregaoker - Executive Vice President, Commercial Bryan McMichael - Chief Financial Officer Confere...
Neutral
GlobeNewsWire
8 days ago
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizu...
Neutral
GlobeNewsWire
15 days ago
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business...
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 228
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today